Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | CA2 | P00918 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.52 |
| ▸ | AQP1 | P29972 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2741867 | 0.89 | KDM4E (0.72) | KDM4EUSP2ALDH1A1CA2LMNA | |
| SCHEMBL2741865 | 0.88 | KDM4E (0.71) | KDM4EUSP2ALDH1A1CA2LMNA | |
| SCHEMBL2741861 | 0.87 | KDM4E (0.72) | KDM4EUSP2ALDH1A1CA2LMNA | |
| SCHEMBL2879559 | 0.87 | KDM4E (0.69) | KDM4EUSP2ALDH1A1CA2LMNA | |
| SCHEMBL2741864 | 0.87 | ALDH1A1 (0.69) | KDM4EUSP2ALDH1A1CA2LMNA | |
| SCHEMBL2875002 | 0.87 | KDM4E (0.69) | KDM4EUSP2ALDH1A1CA2LMNA | |
| SCHEMBL2741873 | 0.86 | CA2 (0.68) | KDM4EUSP2ALDH1A1CA2LMNA | |
| SCHEMBL15495571 | 0.85 | KDM4E (0.67) | KDM4EUSP2ALDH1A1CA2LMNA | |
| SCHEMBL2741860 | 0.84 | KDM4E (0.82) | KDM4EUSP2ALDH1A1CA2LMNA | |
| Bumetanide SCHEMBL27525 | 0.83 | KDM4E (1.00) | KDM4EUSP2ALDH1A1CA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666547-B2 | Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1) | NORTHWESTERN UNIVERSITY (US) | 2023-06-06 | — | — | US | disclosed |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A11, SLC6A13 | KDM4E 2764/4885USP2 3646/4885ALDH1A1 625/4885 |
| US-11666547-B2 | Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1) | SLC6A1, SLC6A3, SLC6A13 | KDM4E 3950/4885USP2 3946/4885ALDH1A1 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.